|1.||Brinckerhoff, Constance E: 12 articles (04/2013 - 01/2002)|
|2.||D'Armiento, Jeanine: 7 articles (08/2015 - 01/2003)|
|3.||Ray, Bimal K: 6 articles (12/2005 - 01/2003)|
|4.||Ray, Alpana: 6 articles (12/2005 - 01/2003)|
|5.||Friedland, Jon S: 5 articles (08/2015 - 10/2005)|
|6.||Scully, Sean P: 5 articles (06/2012 - 11/2003)|
|7.||Sorsa, Timo: 5 articles (12/2011 - 01/2007)|
|8.||Ghahary, Aziz: 4 articles (11/2015 - 07/2010)|
|9.||D'Armiento, Jeanine M: 4 articles (02/2015 - 04/2008)|
|10.||Orbe, Josune: 4 articles (02/2015 - 04/2006)|
09/01/2008 - "Active MMP-1 was most effective in reducing fibrosis, although treatment with proMMP-1 was also beneficial relative to controls. "
09/01/2008 - "Matrix metalloproteinase-1 treatment of muscle fibrosis."
05/17/2005 - "MKK6bE transgenic hearts developed marked interstitial fibrosis with increased matrix metalloproteinase abundance and selective induction of tissue inhibitor of matrix metalloproteinase-1; this extracellular matrix remodeling was also significantly attenuated by p38 inhibition. "
01/01/2004 - "The lack of effect on fibrosis may be due to the persistence of high tissue inhibitor of matrix metalloproteinase-1 expression."
05/01/2003 - "Decreased matrix metalloproteinase-1 (MMP-1) and increased levels of its inhibitor, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), reflect impaired matrix degradation with an increase in fibrosis. "
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
04/21/2005 - "Matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) are central to the spontaneous resolution of liver fibrosis. "
08/01/2000 - "The aim of this study was to investigate the gene expression of interstitial collagenase in the progressive and recovery phases of experimental rat liver fibrosis by in situ hybridization. "
03/01/2014 - "To investigate the function of bone marrow mesenchymal stem cells (BMSCs) with over-expressed matrix metalloproteinase 1 (MMP1) on liver fibrosis. "
08/01/2006 - "The function of the major interstitial collagenase, MMP-13, in the initial phase of liver fibrosis is unknown. "
02/01/2003 - "Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat."
|3.||Hypertension (High Blood Pressure)
08/01/2008 - "Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension."
11/01/2012 - "This study aimed to explore the efficacy of simvastatin on haemodynamic changes, pulmonary vascular remodelling and expression of matrix metalloproteinase-1 and -9 (MMP-1,9) in a carotid artery-jugular vein (CA-JV) shunt pulmonary artery hypertension (PAH) model in rats. "
01/01/2009 - "Aim of the study--investigation of dynamics of levels of serum markers of myocardial fibrosis matrix metalloproteinase-1 (MMP-1), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)--at the background of 3 months hypotensive therapy in 39 patients with arterial hypertension and paroxysmal form of atrial fibrillation. "
08/11/1998 - "We measured serum concentrations of carboxy-terminal telopeptide of collagen type I (CITP) as a marker of extracellular collagen type I degradation, of total matrix metalloproteinase-1 (MMP-1), or collagenase, of total tissue inhibitor of metalloproteinases 1 (TIMP-1), and of MMP-1/TIMP-1 complex in 37 patients with never-treated essential hypertension and in 23 normotensive control subjects. "
01/01/2007 - "Aim of the study was to investigate interrelationship between serum markers of myocardial fibrosis: matrix metalloproteinase -1 (MMP-1), tissue inhibitor of metalloproteinase-1 (TIMP-1) and parameters of echocardiography in patients with arterial hypertension (AH) and paroxysmal form of atrial fibrillation (n=39). "
02/01/2009 - "Our previous studies demonstrated that matrix metalloproteinase-1 (MMP-1) is able to digest fibrous scar tissue and improve muscle healing after injury. "
03/01/2014 - "Kynurenine increases matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and improves scarring in vivo."
10/01/2012 - "In the early period of scar remodeling, the expression of transforming growth factor beta (TGF-β)3 and matrix metalloproteinase 1 (MMP1) was greater in the experimental group than in control group. "
04/15/2007 - "We have recently demonstrated an unequivocal role for scar-associated macrophages (SAMs) in the spontaneous resolution of liver fibrosis and sought to determine whether SAMs are the source of matrix metalloproteinase (MMP) 13 (collagenase 3), considered to be the primary interstitial collagenase in rodents. "
01/01/2013 - "SFN/ASA-treated wounds showed a significantly higher (p < 0.001) expression of matrix metalloproteinase-1, resulting in reduced collagen deposition and less scarring. "
09/01/2002 - "Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia from 3.37+/-2.28% to 5.89+/-2.35% (P<0.001) and lowered plasma levels of C-reactive protein from 0.48 to 0.10 mg/dL (P<0.001), TNF-alpha from 3.38 to 2.79 pg/mL (P<0.001), total matrix metalloproteinase (MMP)-9 from 36 to 28 ng/mL (P=0.006), and tissue inhibitor of matrix metalloproteinase-1 from 80+/-30 to 74+/-23 ng/mL (P=0.041), and simvastatin lowered to a greater extent MMP-9 activity (from 71 to 52 ng/mL, P=0.006) and MMP-9 activity/tissue inhibitor of matrix metalloproteinase-1 ratios (P=0.018), although this difference did not reach statistical significance. "
|1.||Matrix Metalloproteinase 1 (Interstitial Collagenase)
|4.||Matrix Metalloproteinase 9 (Gelatinase B)
|5.||Transforming Growth Factors (Transforming Growth Factor)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||Matrix Metalloproteinase 13
|10.||Type 2 Angiotensin Receptor
|2.||Transplantation (Transplant Recipients)
|3.||Heterologous Transplantation (Xenotransplantation)